Trial ID or NCT#

NCT03833167

Status

recruiting iconRECRUITING

Purpose

This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Anne Lynn S. Chang, MD
Anne Lynn S. Chang, MD
Dermatologist, General dermatologist, Dermatologic oncologist, Cutaneous oncology specialist
Professor of Dermatology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Alexander Valencia
(650) 498-5185